We are excited to celebrate the 5th anniversary of our King Adult Day Enrichment Program (KADEP) at Rocky Mountain MS Center’s facility in Westminster. KADEP is an innovative, community-based and…
Read More
Study results released this week show that an investigational drug, ocrelizumab, significantly reduces the progression of clinical disability in patients with primary progressive multiple sclerosis (PPMS).
Our providers work collaboratively and in a team-based structure. That means that you will be seeing a medical doctor (MD) and advanced practitioners, including physician assistants (PAs) and adult nurse…
The Rocky Mountain MS Center at the University of Colorado is home to one of the largest MS research programs in the world. This unique partnership has created a world-class…
The Rocky Mountain MS Center at University of Colorado is participating in an international survey led by the London School of Economics. The survey is gathering evidence to help compare…
In a study published this month, researchers in Italy found that natalizumab (Tysabri) significantly improved cognitive performance in MS patients over a three year period (Mattioli, et al). This study…
Earlier this month, researchers at University of Virginia released findings of a new study that examined the relationship between the lymphatic system and the brain. The findings were published in…
Dr. Roger Enoka, a professor at the University of Colorado Boulder, has been working closely with physicians from the Rocky Mountain MS Center Clinic at the University of Colorado Anschutz…
The American Academy of Neurology (AAN), established in 1948, is a professional society that represents more than 21,000 neurologists and neuroscientists. The 67th annual AAN Conference was held in Washington,…
In this issue of eMS news, we talked with Kendra Greeney, Exercise Specialist at the King Adult Day Enrichment Program (KADEP) here at the Rocky Mountain MS Center. KADEP is…